Other languages Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
48.48 ^USD	-1.38%		-7.43%	+21.93%

May. 08	Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000	MT
May. 08	Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Morphic Holding Names Simon Cooper as Chief Medical Officer	Mar. 19
Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug	Mar. 15
Keros Therapeutics Gets FDA Fast Track Designation for Anemia Drug	Mar. 14
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	Mar. 14
Keros Therapeutics, Inc. Announces Resignation of Simon Cooper, M.B.B.S., as Chief Medical Officer, Effective March 12, 2024	Mar. 05
Keros Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28
Adipositas-Mittel führen zu Muskelverlust - Pharmafirmen steuern gegen	Jan. 22
Keros Therapeutics Closes $151.3 Million Stock Offering	Jan. 09
Keros Therapeutics Prices Stock Offering at $40 a Share	Jan. 04
Keros Therapeutics Proposes $120 Million Common Stock Offering	Jan. 03
Keros Therapeutics Starts Phase 1 Clinical Trial of Potential Obesity Treatment	Jan. 03
Keros Therapeutics, Inc. to Develop KER-065 for the Treatment of Obesity	Jan. 03
Keros Therapeutics Shares Fall After Reporting Additional Data From Trial of KER-050 With Potential for Treating Cytopenia	Dec. 11
Sector Update: Health Care Stocks Advance Premarket Monday	Dec. 11
Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition	Dec. 11
Keros Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06
Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society	23-10-04
Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Other languages

Filters